絞り込み

17395

広告

日本人も「大きな一歩」を 月面着陸へ日米協力 (毎日新聞)

萩生田光一文部科学相と米航空宇宙局(NASA)のジム・ブライデンスタイン長官は10日、オンラインで会談し、米国の有人月面探査計画の日米協力に関する共同宣言に署名...

  1. 腸内ウイルス、治療に一役 酵素が腸炎菌を...
  2. ヒト受精卵使うゲノム編集了承 厚労省と文...
  3. コロナ後遺症、厚労省調査へ (毎日新聞)...
  4. 新型コロナ アビガン有効性結論出ず 藤田...

ニュース一覧

スターを付ける スターを付ける     (128view , 0users)

Full Text Sources

Multiple myeloma (MM) is a plasma cell malignancy characterized by impaired immune surveillance mechanisms, such as altered antibody production, dysregulation of T cell and natural killer cell proliferation and activation, disruption of antigen presentation processes, and upregulation of checkpoint and immunosuppressive mediators. New and emerging immunotherapeutic agents, such as chimeric antigen receptor (CAR)-engineered T-cell therapies, vaccines, antibody-based therapy, and checkpoint inhibitors, have been developed as a means to target evasion tactics of MM. Herein we summarize the proceedings of "Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient," a workshop held in Havana, Cuba, with contributions from 18 expert hematologic oncologists from the United States, European Union, and Cuba, as well as patient advocacy and industry representatives. The goal of the workshop was to evaluate and discuss key topics and issues regarding development and use of immunotherapies in MM and to collaborate on improving patient outcomes. Clinical significance of recent advances in immunotherapies in MM were discussed, in addition to their current status and therapeutic potential, key issues from various regional perspectives, and opportunities for collaboration to improve MM patient outcomes. In this review we summarize expert presentations on cellular (CAR T cell, allogeneic stem cell transplantation, and vaccine) therapies, antibody-based (daratumumab, elotuzumab, checkpoint inhibitor, anti-cluster of differentiation 28 antibody) therapies, genomics and immunotherapy, and biomarkers of response.
PMID: 31023594 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード